Abstract 932P
Background
Pembrolizumab alone or with platinum-based chemotherapy is a standard first-line systemic treatment for recurent/metastatic (R/M) HNSCC in Europe, based on results of KEYNOTE-048 phase III trial. Real-world data (RWD) are scarce since aprpoval by EMA in 2019. We present real-world data (RWD) of overall survival (OS) of three cohorts of R/M HNSCC patients: cohort 1 (pembrolizumab plus chemotherapy, P+CT), cohort 2 (pembrolizumab alone, P), and cohort 3 (cetuximab plus chemotherapy, C+CT). Data were extracted from TriNetX, the global federated health research network that includes several hospitals in Europe and America.
Methods
The TriNetX network was used to search and analyze clinical anonymized information. The analysis process included two main steps: 1) Defining the cohorts through query criteria: R/M HNSCC, no prior systemic therapy, survival information available, P or P+CT or C+CT. 2) Setting up and running the analysis. Research was done in in a time window of 3 years. Index event was defined as the diagnosis of metastasis. Kaplan-Meier analysis was used to estimate survivals and comparison between cohort 1 vs 3 and cohort 2 vs 3.
Results
Number of patients matching the search criteria were: cohort 1 (P+CT) N=2965, cohort 2 P) N=2138, cohort 3 (C+CT) N=3947. Median age was 61.8, 65.6, and 62.7 yr for cohort 1, 2, and 3, respectively. Male percentage was 74.8%, 72.8%, and 78.3%, respectively. Primary tumor in oropharynx was present in 37.4%, 16.2% and 54.2%, respectively. Unspecified or ill-defined primary tumor location was present in 32.5%, 23.4%, and 43.1%, respectively. Information about PD-L1 status was not available. Median OS for cohort 1 and 2 were not reached; it was 951 days for cohort 3. Log-rank comparison was significantly different for cohort 1 vs 3 (p<0.001), and for 2 vs 3 (p<0.001), demonstrating superiority for either of the anti-PD1 cohorts.
Conclusions
OS with pembrolizumab-based therapy is superior compared to cetuximab plus CT in these RWD cohorts of first-line treatment for R/M HNSCC. An unexpected high median overall survival was found in all cohorts. The TriNetX system has limitations that must be detected and improved.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L. Ugidos De La Varga: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: MSD, BMS, Merck. All other authors have declared no conflicts of interest.
Resources from the same session
931P - Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) patients
Presenter: Pasvich Pitakpaiboonkul
Session: Poster session 12
934P - Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Presenter: Hongli Gong
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12